Cancer is becoming a major cause of death worldwide. With the increase in life expectancy, the number of cancer cases has reached peak levels. In this scenario, the pharmaceutical industry has made significant investments in this therapeutic area. Despite these efforts, cancer drug research remains a remarkably challenging field, and therapeutic innovations have not yet achieved anticipated clinical results. However, the pathophysiology of the disease is now better understood, and the discovery of novel molecular targets has raised the expectations of developing improved treatments. Several noteworthy advances have been made, among which the development of targeted therapies is the most improvement. Monoclonal antibodies and antibody-small molecule conjugates have emerged as an effective approach to improve drug selectivity and reduce adverse effects, which are the main challenges in cancer drug discovery.
All accepted abstracts will be published in respective Allied Academies Journals.
Abstracts will be provided with Digital Object Identifier by
